FY2025 EPS Estimates for Humana Lifted by Cantor Fitzgerald

Humana Inc. (NYSE:HUM) – Stock analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Humana in a research note issued to investors on Thursday, July 31st. Cantor Fitzgerald analyst S. James now anticipates that the insurance provider will post earnings of $17.02 per share for the year, up from their prior estimate of $16.32. Cantor Fitzgerald has a “Neutral” rating and a $290.00 price target on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Cantor Fitzgerald also issued estimates for Humana’s FY2026 earnings at $13.86 EPS.

Several other research analysts also recently issued reports on the company. Raymond James Financial raised Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a research note on Thursday, May 1st. Oppenheimer upped their price target on shares of Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a report on Thursday, May 1st. Mizuho raised their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 9th. Barclays set a $275.00 price objective on Humana and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Piper Sandler lowered their target price on Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a report on Thursday. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $281.62.

Humana Stock Down 1.1%

HUM opened at $247.19 on Friday. Humana has a one year low of $206.87 and a one year high of $382.72. The company has a market cap of $29.73 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.66 and a beta of 0.44. The business’s fifty day moving average is $235.09 and its two-hundred day moving average is $255.24. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.91 and a current ratio of 1.95.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%. The firm had revenue of $32.39 billion for the quarter, compared to analysts’ expectations of $31.85 billion. During the same period last year, the firm earned $6.96 EPS. Humana’s revenue was up 9.6% compared to the same quarter last year.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently made changes to their positions in the stock. Revolve Wealth Partners LLC purchased a new stake in Humana during the fourth quarter valued at about $202,000. American Century Companies Inc. lifted its stake in shares of Humana by 8.8% in the 4th quarter. American Century Companies Inc. now owns 12,655 shares of the insurance provider’s stock valued at $3,211,000 after purchasing an additional 1,027 shares in the last quarter. Orion Portfolio Solutions LLC grew its holdings in shares of Humana by 3.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider’s stock worth $1,226,000 after purchasing an additional 171 shares during the period. Summit Financial LLC increased its position in Humana by 19.2% during the 4th quarter. Summit Financial LLC now owns 1,409 shares of the insurance provider’s stock worth $359,000 after purchasing an additional 227 shares in the last quarter. Finally, HighPoint Advisor Group LLC raised its holdings in Humana by 6.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 1,509 shares of the insurance provider’s stock valued at $388,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.